1.
两组患者的基线资料
Baseline data of the two groups of patients
| Parameter | Study group (n=50) | Control group (n=50) | χ2/t | P |
| CCyR: Complete cytogenetic response. MMR: Major molecular response. | ||||
| Age at diagnosis (year) | 36.52±11.20 | 35.98±12.35 | 0.229 | 0.819 |
| Gender (Male/Female) | 25/25 | 27/22 | 0.258 | 0.611 |
| Imatinib dose at CCyR (mg) | 1.198 | 0.549 | ||
| 300 | 4(36.00%) | 7(64.00%) | ||
| 400 | 44(51.00%) | 42(49.00%) | ||
| 600 | 2(67.00%) | 42(49.00%) | ||
| Sokal score | 2.564 | 0.277 | ||
| Low | 12(39.00%) | 19(61.00%) | ||
| Intermediate | 26 (53.00%) | 23 (47.00%) | ||
| High | 12(60.00) | 8 (40.00%) | ||
| EUTOS score | 0.219 | 0.640 | ||
| Low | 37 (49.00%) | 39 (51.00%) | ||
| High | 13 (54.00%) | 11 (46.00%) | ||
| Hasford score | 0.401 | 0.818 | ||
| Low | 17(46.00%) | 20 (54.00%) | ||
| Intermediate | 30 (53.00%) | 27 (47.00%) | ||
| High | 3 (50.00%) | 3 (50.00%) | ||
| Attainment of MMR | 11 (22.00%) | 38 (76.00%) | 29.172 | 0.000 |
| Duration of follow-up (month) | 45.94±8.52 | 45.75±9.14 | 0.108 | 0.915 |